- Home
- LOBO vs NRSN Comparison
LOBO vs NRSN Comparison
Compare LOBO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOBO
- NRSN
- Stock Information
- Founded
- LOBO 2014
- NRSN 2017
- Country
- LOBO China
- NRSN Israel
- Employees
- LOBO N/A
- NRSN N/A
- Industry
- LOBO
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- LOBO
- NRSN Health Care
- Exchange
- LOBO NYSE
- NRSN Nasdaq
- Market Cap
- LOBO 19.9M
- NRSN 14.4M
- IPO Year
- LOBO 2024
- NRSN 2021
- Fundamental
- Price
- LOBO $2.15
- NRSN $0.94
- Analyst Decision
- LOBO
- NRSN
- Analyst Count
- LOBO 0
- NRSN 0
- Target Price
- LOBO N/A
- NRSN N/A
- AVG Volume (30 Days)
- LOBO 13.3K
- NRSN 307.8K
- Earning Date
- LOBO 09-17-2024
- NRSN 09-13-2024
- Dividend Yield
- LOBO N/A
- NRSN N/A
- EPS Growth
- LOBO N/A
- NRSN N/A
- EPS
- LOBO 0.15
- NRSN N/A
- Revenue
- LOBO $15,474,918.00
- NRSN N/A
- Revenue This Year
- LOBO $21.23
- NRSN N/A
- Revenue Next Year
- LOBO $34.66
- NRSN N/A
- P/E Ratio
- LOBO $13.99
- NRSN N/A
- Revenue Growth
- LOBO N/A
- NRSN N/A
- 52 Week Low
- LOBO $1.76
- NRSN $0.40
- 52 Week High
- LOBO $4.70
- NRSN $2.33
- Technical
- Relative Strength Index (RSI)
- LOBO N/A
- NRSN 61.17
- Support Level
- LOBO N/A
- NRSN $0.67
- Resistance Level
- LOBO N/A
- NRSN $0.85
- Average True Range (ATR)
- LOBO 0.00
- NRSN 0.09
- MACD
- LOBO 0.00
- NRSN 0.03
- Stochastic Oscillator
- LOBO 0.00
- NRSN 84.64
About LOBO LOBO EV TECHNOLOGIES LTD
Lobo EV Technologies Ltd is an electric vehicle manufacturer and seller company. It designs, develops, manufactures, and sells e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons, also provides automobile information and entertainment software development and design services to customers. The company operates in two operating segments: Electric vehicles and accessories sales which generates key revenue, and software royalties and development and design services. It generates all of its revenue within the People's Republic of China.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.